scroll to top

EBSCO Auth Banner

Let's find your institution. Click here.

In vitro characterization studies of self-microemulsified bosentan systems.

  • Academic Journal
  • Vadlamudi HC; a Department of Pharmaceutics, Centre for Research Studies , Krishna University , Machilipatnam , India.; b Department of Pharmaceutics , PES College of Pharmacy , Bangalore , India.
    Yalavarthi PR; c Division of Pharmaceutics , Sri Padmavathi School of Pharmacy , Tirupati , India.
    M V BR; d Department of Chemistry , Krishna University , Machilipatnam , India.
    Rasheed A; e Department of Chemistry , Al-Shifa College of Pharmacy , Poonthavanam , India.
    N T; c Division of Pharmaceutics , Sri Padmavathi School of Pharmacy , Tirupati , India.
  • Drug development and industrial pharmacy [Drug Dev Ind Pharm] 2017 Jun; Vol. 43 (6), pp. 989-995. Date of Electronic Publication: 2017 Feb 16.
  • English
  • Context: Bosentan is a poorly soluble drug and pose challenges in designing of drug delivery systems.
    Objective: The objective of this study is to enhance the solubility, dissolution and shelf-life of bosentan by formulating it as S-SMEDDS capsules.
    Materials and Methods: Solubility of bosentan was tested in various liquid vehicles such as oils (rice bran and sunflower), surfactants (span 20 and tween 80) and co-surfactants (PEG 400 and propylene glycol) and microemulsions were developed. Bosentan was incorporated into appropriate microemulsion systems which were previously identified from pseudo ternary phase diagrams. Bosentan-loaded SMEDDS were evaluated for drug content, drug release, zeta potential, and droplet size. The selected liquid SMEDDS were converted into solid SMEDDS by employing adsorption and melt granulation. Solid SMEDDS were characterized for micromeritics and evaluated for drug content, drug release, and shelf-life.
    Results: Isotropic systems R5, R13, S5, and S13 with submicron droplet size had exhibited 85.45, 94.12, 81.67, and 96.64% drug release, respectively. Solid SMEDDS of MR13 and AS13 formulations with rapid reconstitution ability, exhibited 84.85 and 86.74% of on par drug release. The formulations were physicochemically intact for 1.02 and 1.56 years.
    Discussion: Liquid SMEDDS composed with PEG400 had displayed optimal characters. Solid SMEDDS had high-dissolution profiles than bosentan due to modification in the crystalline structure of drug upon microemulsification.
    Conclusion: Thus, solid SMEDDS addressed the solubility, dissolution, and stability issues of bosentan and becomes an alternate for clinical convenience.
Additional Information
Publisher: Informa Healthcare Country of Publication: England NLM ID: 7802620 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-5762 (Electronic) Linking ISSN: 03639045 NLM ISO Abbreviation: Drug Dev Ind Pharm Subsets: MEDLINE
Publication: London : Informa Healthcare
Original Publication: New York, Dekker.
Keywords: Phase diagram; bioavailability; endothelin; microemulsion; zeta potential
0 (Antihypertensive Agents)
0 (Capsules)
0 (Emulsions)
0 (Plant Oils)
0 (Sulfonamides)
Q326023R30 (Bosentan)
Date Created: 20170126 Date Completed: 20170809 Latest Revision: 20181202